Packaging for diagnostic tests. MBM were able to offer Lumira DX a one-stop-shop for everything, and we easily accommodated additions to Lumira’s portfolio within their Point-of-Care platform.

When Covid hit, though, everything changed. While Lumira’s regular products became less of a priority, all efforts went in to providing rapid antigen (Ag) and antibody (Ab) testing kits. Volumes were huge, and we were providing tens of thousands of test strip labels, test strip packaging and all the ancillary printed items that went into the kits on a daily basis.

On top of this, each kit required a buffer solution which is used in the Covid testing process, and each of these buffer vials had to be batch controlled and labelled. Lumira shared this task with MBM, and a batch of 192,000 vials would initially take roughly two weeks to label by hand.

Grasping the opportunity to reduce the timescale for this task, MBM invested in a first vial labelling machine, quickly followed by a second. This game-changing move meant we could now label a batch of 192,000 vials in just 48 hours: in other words, two days instead of two weeks. This allowed Lumira DX to vastly increase its supply to the market throughout Europe.

Since the threat of Covid has reduced significantly over the past couple of years, Lumira DX have now returned to developing all the various ‘markers’ their Point-of-Care platform can diagnose, and they now have CE Marks for 12 different tests, with many more in the pipeline. MBM continue to provide all the print, packaging and labels for all of these different tests.